dipraglurant
Small moleculeexperimental
Dipraglurant is a negative allosteric modulator of the mGlu5 receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). As of 2014, it is in phase II clinical trials for this indication. Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia. — Wikipedia
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01336088)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 5MODULATOR
GRM5 modulator
Chemistry & pharmacology
Loading structure…
SMILES
Fc1ccc2nc(CCC#Cc3ccccn3)cn2c1- Mol. weight
- 265.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDipraglurant ↗
- ChEMBLCHEMBL2346738 ↗
Also known as
- 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine
- adx48621
- adx48621
- adx48621
- dipraglurant
- dipraglurant
- dipraglurant
- dipraglurant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05116813 | Phase 2/Phase 3 (Phase 3) | Oct 25, 2021 | Addex Pharma |
| NCT05027997 | Phase 2 | Oct 6, 2021 | Addex Pharma |
| NCT04857359 | Phase 2/Phase 3 (Phase 3) | Aug 6, 2021 | Addex Pharma |
| NCT02447640 | Phase 1 | Apr 1, 2015 | Addex Pharma, Johns Hopkins University |
| NCT01336088 | Phase 2 | Apr 1, 2011 | Addex Pharma |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Addex Pharma | For profit | 5 | 4 | 3 | 2011 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1